Full Text View
Tabular View
No Study Results Posted
Related Studies
The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
This study has been completed.
Study NCT00159861   Information provided by Pfizer
First Received: September 8, 2005   Last Updated: April 4, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pulmonary Hypertension
Additional conditions recognized in this trial
Hypertension
Hypertension, Pulmonary
More general conditions related to this trial
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Interventions listed in this trial
Sildenafil citrate
Additional drug interventions recognized in this trial
Citric Acid
Epoprostenol
Sildenafil
More general drug interventions related to this trial
Anticoagulants
Antihypertensive Agents
Cardiovascular Agents
Chelating Agents
Enzyme Inhibitors
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase Inhibitors
Platelet Aggregation Inhibitors
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services